Newswire (Published: Thursday, January 31, 2019, 4:00:00 PM CST, Received: Thursday, January 31, 2019, 8:19:24 PM CST)
Word Count: 380
By a News Reporter-Staff News Editor at Cancer Weekly -- A new study on Oncology - Prostate Cancer is now available. According to news reporting from Oxford, United Kingdom, by NewsRx journalists, research stated, "More than a million men worldwide are diagnosed with prostate cancer every year. After androgen deprivation therapy (ADT), chemotherapy has been the only subsequent intervention to improve survival in the metastatic setting but has limitations for patients who may not tolerate its toxicity profile or are not candidates on the basis of comorbidities."
The news correspondents obtained a quote from the research from Oxford University Hospitals NHS Foundation Trust, "Novel anti-androgens such as abiraterone acetate have shown promise for such patients. This review draws on clinical evidence and experience to identify abiraterone as a well-tolerated, effective alternative to docetaxel. In the castration-resistant setting, studies demonstrated a survival benefit over placebo, prompting further trials in the hormone-na?ve population. More recently the STAMPEDE and LATITUDE studies suggest abiraterone has comparable survival outcomes to docetaxel in the castration-sensitive setting, with evidence in favour of its quality of life profile. Available comparisons with docetaxel are limited, but those available suggest they have comparable efficacy. However, the significant cost compared with docetaxel is a major barrier in resource-rationed healthcare settings."
According to the news reporters, the research concluded: "Overall, abiraterone is an effective alternative to chemotherapy for men with castration-sensitive prostate cancer, but this should be balanced with the significantly greater cost."
For more information on this research see: Abiraterone acetate in combination with prednisone in the treatment of metastatic hormone-sensitive prostate cancer: clinical evidence and experience. Therapeutic Advances in Urology, 2019;11():175628721882080. (Sage Publications - www.sagepub.com/; Therapeutic Advances in Urology - tau.sagepub.com)
Our news journalists report that additional information may be obtained by contacting K. Purshouse, Oxford University Hospitals NHS Foundation Trust, Churchill Hospital, Headington, Oxford, OX3 7LE, UK (see also Oncology - Prostate Cancer).
The direct object identifier (DOI) for that additional information is: https://doi.org/10.1177/1756287218820804. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.
(Our reports deliver fact-based news of research and discoveries from around the world.)
Science and Technology
Health and Wellness
Medical Conditions and Diseases
Men's Health Issues
Medical Specialties and Practices